Viking Therapeutics, INC. (VKTX) — SEC Filings

Overview

Viking Therapeutics, INC. (VKTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 23, 2025: Viking Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $201.977 million, a substantial rise from $74.546 million in the same period of 2024. This 171% increase was primarily driven by a surge in research and development (R&D) expe

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 33 neutral, 1 mixed. The dominant filing sentiment for Viking Therapeutics, INC. is neutral.

Filing Type Overview

Viking Therapeutics, INC. (VKTX) has filed 1 ARS, 6 10-Q, 14 8-K, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (36)

• ARS Filing — ARS · Apr 1, 2026
• Viking's R&D Surge Drives 171% Net Loss Increase to $202M — 10-Q · Oct 23, 2025 Risk: high
  Viking Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $201.977 million, a substantial ris
• Viking Therapeutics Files 8-K on Financials — 8-K · Oct 22, 2025 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on October 22, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Viking Therapeutics Files 8-K Report — 8-K · Aug 19, 2025 Risk: low
  On August 19, 2025, Viking Therapeutics, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes Fina
• Viking Therapeutics' Losses Widen Amid R&D Surge, Cash Position Strong — 10-Q · Jul 23, 2025 Risk: medium
  Viking Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage biotechnology status. The com
• Viking Therapeutics Files 8-K on Shareholder Votes & Exhibits — 8-K · May 27, 2025 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits as of May
• Viking Therapeutics Files Q1 2025 10-Q — 10-Q · Apr 24, 2025 Risk: medium
  Viking Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations, includ
• Viking Therapeutics Files 8-K: Auditor Change — 8-K · Apr 23, 2025 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on April 23, 2025, reporting events as of April 18, 2025. The filing primarily concerns changes in the registrant's certi
• Viking Therapeutics DEF 14A: Executive Compensation Details — DEF 14A · Apr 8, 2025 Risk: low
  Viking Therapeutics, Inc. filed a DEF 14A on April 8, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2021, 20
• Viking Therapeutics Files 8-K on Material Agreement — 8-K · Mar 11, 2025 Risk: medium
  On March 10, 2025, Viking Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered in
• Viking Therapeutics Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
  Viking Therapeutics, Inc. filed its 2024 10-K on February 26, 2025, reporting its fiscal year ending December 31, 2024. The company, operating in pharmaceutical
• Viking Therapeutics Files 8-K on Financials — 8-K · Feb 5, 2025 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on February 5, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Viking Therapeutics Files 8-K — 8-K · Nov 4, 2024 Risk: low
  On November 4, 2024, Viking Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statem
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Viking Therapeutics Files Q3 2024 10-Q — 10-Q · Oct 23, 2024 Risk: medium
  Viking Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and results of operations, in
• SC 13G/A Filing — SC 13G/A · Oct 18, 2024
• SC 13G/A Filing — SC 13G/A · Aug 7, 2024
• Viking Therapeutics Files Q2 2024 10-Q — 10-Q · Jul 24, 2024 Risk: medium
  Viking Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial position and operational highlights. Key financ
• Viking Therapeutics Files 8-K — 8-K · Jun 4, 2024 Risk: low
  On June 4, 2024, Viking Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
• Viking Therapeutics Announces Annual Meeting Results — 8-K · May 23, 2024 Risk: low
  Viking Therapeutics, Inc. announced on May 21, 2024, several key updates. The company held its Annual Meeting of Stockholders where directors were elected and a
• Viking Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 25, 2024 Risk: medium
  Viking Therapeutics, Inc. (VKTX) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Viking Therapeutics, Inc. filed a 10-Q report for the quarter e
• Viking Therapeutics Files 8-K on Operations — 8-K · Apr 24, 2024 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on April 24, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Viking Therapeutics Files DEF 14A with SEC — DEF 14A · Apr 5, 2024 Risk: low
  Viking Therapeutics, Inc. (VKTX) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Viking Therapeutics, Inc. filed a DEF 14A form with the SEC on
• Viking Therapeutics Files 8-K — 8-K · Mar 26, 2024 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on March 26, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Viking Therapeutics Files 8-K — 8-K · Mar 4, 2024 Risk: low
  Viking Therapeutics, Inc. filed an 8-K on March 4, 2024, to report other events and financial statements. The filing does not contain specific financial figures
• Viking Therapeutics Files 8-K Report — 8-K · Mar 1, 2024 Risk: low
  On February 28, 2024, Viking Therapeutics, Inc. filed an 8-K report detailing several events. The company entered into a material definitive agreement and repor
• Viking Therapeutics Files Routine 8-K for Regulatory Disclosure — 8-K · Feb 27, 2024 Risk: low
  Viking Therapeutics, Inc. filed a Form 8-K with the SEC on February 27, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. This
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• FMR LLC & Abigail Johnson Report 14.999% Stake in Viking Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its Chairman and CEO, Abigail P. Johnson, have updated their ownership stake in Viking Therapeutics, Inc. (VKNG) through a
• Viking Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 7, 2024 Risk: medium
  Viking Therapeutics, Inc. (VKTX) filed a Annual Report (10-K) with the SEC on February 7, 2024. Viking Therapeutics, Inc. filed its 2023 Form 10-K on February 7
• BlackRock Discloses Passive Stake in Viking Therapeutics (VKNG) — SC 13G · Jan 26, 2024
  BlackRock Inc., a major investment firm, reported on January 26, 2024, that as of December 31, 2023, it holds a significant stake in Viking Therapeutics, Inc. (
• State Street Corp. Amends Viking Therapeutics Stake Disclosure — SC 13G/A · Jan 24, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Viking Therapeutics Inc. com
• Millennium Management Updates VKTX Stake as of Dec 31, 2023 — SC 13G/A · Jan 12, 2024
  Millennium Management LLC, a Delaware-based investment firm, filed an amended SC 13G/A on January 12, 2024, disclosing its holdings in Viking Therapeutics, Inc.

Related Companies

VKTR

Frequently Asked Questions